[Federal Register Volume 61, Number 164 (Thursday, August 22, 1996)]
[Notices]
[Pages 43370-43372]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-21358]


-----------------------------------------------------------------------


DEPARTMENT OF HEALTH AND HUMAN SERVICES

Advisory Committees; Notice of Meetings

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This notice announces forthcoming meetings of public advisory 
committees of the Food and Drug Administration (FDA). This notice also 
summarizes the procedures for the meetings and methods by which 
interested persons may participate in open public hearings before FDA's 
advisory committees.

    FDA has established an Advisory Committee Information Hotline (the 
hotline) using a voice-mail telephone system. The hotline provides the 
public with access to the most current information on FDA advisory 
committee meetings. The advisory committee hotline, which will 
disseminate current information and information updates, can be 
accessed by dialing 1-800-741-8138 or 301-443-0572. Each advisory 
committee is assigned a 5-digit number. This 5-digit number will appear 
in each individual notice of meeting. The hotline will enable the 
public to obtain information about a particular advisory committee by 
using the committee's 5-digit number. Information in the hotline is 
preliminary and may change before a

[[Page 43371]]

meeting is actually held. The hotline will be updated when such changes 
are made.
MEETINGS: The following advisory committee meetings are announced:
Endocrinologic and Metabolic Drugs Advisory Committee
    Date, time, and place. September 26, 1996, 8 a.m., Holiday Inn--
Bethesda, Versailles Ballrooms I and II, 8120 Wisconsin Ave., Bethesda, 
MD.
    Type of meeting and contact person. Open public hearing, 8 a.m. to 
9 a.m., unless public participation does not last that long; open 
committee discussion, 9 a.m. to 5 p.m.; Kathleen R. Reedy or LaNise S. 
Giles, Center for Drug Evaluation and Research (HFD-21), Food and Drug 
Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-5455, 
or FDA Advisory Committee Information Hotline, 1-800-741-8138 (301-443-
0572 in the Washington, DC area), Endocrinologic and Metabolic Drugs 
Advisory Committee, code 12536. Please call the hotline for information 
concerning any possible changes.
    General function of the committee. The committee reviews and 
evaluates data on the safety and effectiveness of marketed and 
investigational human drugs for use in endocrine and metabolic 
disorders.
    Agenda--Open public hearing. Interested persons may present data, 
information, or views, orally or in writing, on issues pending before 
the committee. Those desiring to make formal presentations should 
notify the contact person before September 18, 1996, and submit a brief 
statement of the general nature of the evidence or arguments they wish 
to present, the names and addresses of proposed participants, and an 
indication of the approximate time required to make their comments.
    Open committee discussion. The committee will hear presentations 
and discuss the safety and efficacy of a new drug application (NDA) 20-
632, sibutramine hydrochloride monohydrate, (MeridiaTM, Knoll 
Pharmaceutical Co.) for weight loss in obesity.
Blood Products Advisory Committee
    Date, time, and place. September 26 and 27, 1996, 8 a.m., Holiday 
Inn--Bethesda, Versailles Ballrooms II and III, 8120 Wisconsin Ave., 
Bethesda, MD.
    Type of meeting and contact person. Open committee discussion, 
September 26, 1996, 8 a.m. to 9:15 a.m.; open public hearing, 9:15 a.m. 
to 9:45 a.m., unless public participation does not last that long; open 
committee discussion, 9:45 a.m. to 11:30 a.m.; open public hearing, 
11:30 a.m. to 12 m., unless public participation does not last that 
long; open committee discussion, 12 m. to 3 p.m.; open public hearing, 
3 p.m. to 3:30 p.m., unless public participation does not last that 
long; open committee discussion, 3:30 p.m. to 5 p.m.; open committee 
discussion, September 27, 1996, 8 a.m. to 9:30 a.m.; open public 
hearing, 9:30 a.m. to 10 a.m., unless public participation does not 
last that long; open committee discussion, 10 a.m. to 12 m.; Linda A. 
Smallwood, Center for Biologics Evaluation and Research (HFM-350), Food 
and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, 301-
827-3514, or FDA Advisory Committee Information Hotline, 1-800-741-8138 
(301-443-0572 in the Washington, DC area) Blood Products Advisory 
Committee, code 12388. Please call the hotline for information 
concerning any possible changes.
    General function of the committee. The committee reviews and 
evaluates data on the safety and effectiveness, and appropriate use of 
blood products intended for use in the diagnosis, prevention, or 
treatment of human diseases.
    Agenda--Open public hearing. Interested persons may present data, 
information, or views, orally or in writing, on issues pending before 
the committee. Those desiring to make formal presentations should 
notify the contact person before September 16, 1996, and submit a brief 
statement of the general nature of the evidence or arguments they wish 
to present, the names and addresses of proposed participants, and an 
indication of the approximate time required to make their comments.
    Open committee discussion. On the morning of September 26, 1996, 
the committee will hear informational presentations on detection of the 
human immunodeficiency virus (HIV)-1 Group ``O'' and on the possible 
transmission of hepatitis C (HCV) by Immune Globulin. In the afternoon, 
the committee will review issues concerning recombinant Factor VIIa, 
Novo Nordisk. On September 27, 1996, the committee will sit as a 
Medical Device Panel to review and make recommendations on the 
reclassification of the Autopheresis-C System, a rotating membrane 
filtration blood separator, Fenwal Division, Baxter Healthcare Corp.
    FDA public advisory committee meetings may have as many as four 
separable portions: (1) An open public hearing, (2) an open committee 
discussion, (3) a closed presentation of data, and (4) a closed 
committee deliberation. Every advisory committee meeting shall have an 
open public hearing portion. Whether or not it also includes any of the 
other three portions will depend upon the specific meeting involved. 
There are no closed portions for the meetings announced in this notice. 
The dates and times reserved for the open portions of each committee 
meeting are listed above.
    The open public hearing portion of each meeting shall be at least 1 
hour long unless public participation does not last that long. It is 
emphasized, however, that the 1 hour time limit for an open public 
hearing represents a minimum rather than a maximum time for public 
participation, and an open public hearing may last for whatever longer 
period the committee chairperson determines will facilitate the 
committee's work.
    Public hearings are subject to FDA's guideline (subpart C of 21 CFR 
part 10) concerning the policy and procedures for electronic media 
coverage of FDA's public administrative proceedings, including hearings 
before public advisory committees under 21 CFR part 14. Under 21 CFR 
10.205, representatives of the electronic media may be permitted, 
subject to certain limitations, to videotape, film, or otherwise record 
FDA's public administrative proceedings, including presentations by 
participants.
    Meetings of advisory committees shall be conducted, insofar as is 
practical, in accordance with the agenda published in this Federal 
Register notice. Changes in the agenda will be announced at the 
beginning of the open portion of a meeting.
    Any interested person who wishes to be assured of the right to make 
an oral presentation at the open public hearing portion of a meeting 
shall inform the contact person listed above, either orally or in 
writing, prior to the meeting. Any person attending the hearing who 
does not in advance of the meeting request an opportunity to speak will 
be allowed to make an oral presentation at the hearing's conclusion, if 
time permits, at the chairperson's discretion.
    The agenda, the questions to be addressed by the committee, and a 
current list of committee members will be available at the meeting 
location on the day of the meeting.
    Transcripts of the open portion of the meeting may be requested in 
writing from the Freedom of Information Office (HFI-35), Food and Drug 
Administration, rm. 12A-16, 5600 Fishers Lane, Rockville, MD 20857, 
approximately 15 working days after the meeting, at a cost of 10 cents 
per page.

[[Page 43372]]

The transcript may be viewed at the Dockets Management Branch (HFA-
305), Food and Drug Administration, rm. 1-23, 12420 Parklawn Dr., 
Rockville, MD 20857, approximately 15 working days after the meeting, 
between the hours of 9 a.m. and 4 p.m., Monday through Friday. Summary 
minutes of the open portion of the meeting may be requested in writing 
from the Freedom of Information Office (address above) beginning 
approximately 90 days after the meeting.
    This notice is issued under section 10(a)(1) and (a)(2) of the 
Federal Advisory Committee Act (5 U.S.C. app. 2), and FDA's regulations 
(21 CFR part 14) on advisory committees.

    Dated: August 15, 1996.
Michael A. Friedman,
Deputy Commissioner for Operations.
[FR Doc. 96-21358 Filed 8-21-96; 8:45 am]
BILLING CODE 4160-01-F